Sage Journals: Discover world-class research

Open access

Research article

First published 2020-7

Anti-JCV antibody index does not change during ocrelizumab-treatment

Torge Rempe, Aaron Carlson, Augusto Miravalle [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2025

Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV antibody detection in natalizumab-treated RRMS patients

Clara Grazia Chisari, Giulio Spampinato, Pina Crimì [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Research article

First published 2016-7

PML risk stratification using anti-JCV antibody index and L-selectin

Nicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2016-12

Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy

A. Salmen, N. von Ahsen, A.K. Trampe [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2013-10

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Tomas Olsson, Anat Achiron, Lars Alfredsson [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2013-6

The effect of plasma exchange on serum anti-JC virus antibodies

Meena Subramanyam, Tatiana Plavina, Bhupendra O Khatri [...]

Multiple Sclerosis Journal

Retricted access

Editorial

First published 2025-6

Diagnostic uncertainty in the era of biosimilar natalizumab—The case for harmonizing anti-JCV antibody testing

Tjalf Ziemssen, Diego Centonze

Multiple Sclerosis Journal

Retricted access

Research article

First published 2015-10

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

Anke Vennegoor, Johannis A van Rossum, Chris H Polman [...]

Multiple Sclerosis Journal

Retricted access

Letter

First published 2025-3

Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice

Hernan Inojosa, Annika Kather, Katja Akgün [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2024-6

The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis

Stephen C Krieger, Susie Sinks, Furong Huang [...]

Multiple Sclerosis Journal

Search results